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1. Introduction
Sarcoidosis  is  a  multi-system,  T-helper  1  (Th1)  cell  biased granulomatous  disorder.  The
current hypothesis is that sarcoidosis develops in a genetically predisposed individual who
is  exposed  to  a  yet  unknown  environmental  trigger(s)  [1].  Antigen  presentation  in  the
context  of  major  histocompatibility  complex  II  (MHC-II)  activates  Th1  cells  with  subse‐
quent production of various cytokines and chemokines including but not limited to IFN-
γ, TNF-α, TGF-β, IL-2,  IL-12 and others leading to further immune cell  recruitment and
activation [2]. The immune response ultimately leads to the formation of granulomas which
consist of a central core of mononuclear cells surrounded by CD4+ cells and a small number
of CD8+ and B-cells [2]. A role for regulatory T-cells has been proposed but their exact role
in sarcoidosis is yet unknown [3].
The disparity in prevalence and variability of organ involvement between ethnic groups
[1] and the familial clustering of sarcoidosis strongly support a genetic basis for sarcoido‐
sis  [4].  Several  genome  wide  associations  studies  (GWAS)  have  identified  potential
association between specific  genetic  loci  and sarcoidosis  [5-11]  and several  studies  have
also associated various human leukocyte antigen (HLA) markers and gene-specific single
nucleotide polymorphisms (SNP) with the risk, disease course and organ involvement with
sarcoidosis indicating that sarcoidosis is  a polygenic disease.  Adding to this complexity,
certain genetic markers have shown an association based on ethnicity and gender and some
have shown differential associations based on gender and ethnicity [34]. Genetic polymor‐
phisms that are functional can potentially influence the immune system’s recognition of an
antigen  and  the  subsequent  immune  response  to  the  antigen  thus  dictating  disease
phenotype (Figure 1).
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Figure 1. Functional genetic polymorphisms dictate immune response and disease phenotype
Genetic studies have played an important role in revealing new pathways and mechanisms
involved in the pathogenesis of immune mediated diseases such as rheumatoid arthritis,
inflammatory bowel disease, psoriasis, systemic lupus erythematosus, type 1 diabetes and
others [12]. Genome-wide association studies investigate the potential association of a disease
with genetic markers across the entire genome without a mechanistic hypothesis [13]. Thou‐
sands of representative SNPs (tagging SNPs) that span the whole genome are assayed for
potential association with a specific disease. In contrast, a candidate-gene approach is hypoth‐
esis driven and investigates the potential association of disease with polymorphisms in a
specific gene(s) that encode molecule(s) (receptor, cytokine, signal transduction…) that are
involved in the pathogenesis of a disease [13]. Familial-genetic studies investigate the associ‐
ation of genetic markers with a rare disease. Family members of an affected individual are
studied for genetic markers that are present in affected members but absent in others [13].
Several environmental and infectious agents have been proposed to be associated with
sarcoidosis but none proven yet. The ACCESS (A Case Controlled Etiological Study in
Sarcoidosis) study group identified 5 occupations and 5 exposures that were more prevalent
in sarcoidosis patients [14]. These exposures included agricultural employment, physicians,
jobs raising birds, jobs in automotive manufacturing and middle/secondary school teachers,
insecticides, employment in pesticide-using industries, occupational exposure to mold and
mildew, occupational exposure to musty odors and use of home central air-conditioning [14].
In contrast, smoking appears to be protective against sarcoidosis [14, 15]. Infectious agents,
particularly Mycobateria, are re-emerging as a potential antigen in sarcoidosis with studies
detecting Mycobacteria proteins in tissues from sarcoidosis patients and T-cells from sarcoi‐
dosis patients responding to stimulation by Mycobacterial antigens [16-23]. Recent studies
have also demonstrated an interaction between genetic markers and in vitro immune respons‐
es to Mycobacterial antigens further supporting the gene-environment interaction theory. [22]
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In this review, we will attempt to summarize the current literature on the association of genetic
markers with sarcoidosis from a functional perspective and highlight differences that might
exist between different racial groups.
Genetic markers and risk of disease (Table 1):
Gene Polymorphism Population OR CI p Ref
Lofgren's
Syndrome
HLA DRB1*03 White UK/Dutch 7.97 4.16-15.26 <0.0001 [26]
DRB1*0301 White Spanish 3.52 1.83-6.79 0.0004 [27]
DRB1*0301 White Swedish 7.71 4.63-12.84 <0.0001 [27]
DRB1*03 White Swedish 6.71 NR <0.0001 [28]
DRB1*03-DQB1*0201 White Dutch 12.5 5.69-27.52 <0.0001 [29]
DRB1*0301 Finnish 2.46 1.11-5.45 0.044 [33]
DRB1*1501 Finnish 2.16 1.06-4.41 0.037 [33]
MHC2TA rs3087456G White Swedish 1.31† 1.04-1.65† .019 [31]
rs11074932C White Swedish 1.27† 1.02-1.58† .026 [31]
BTNL2 rs3117099T White UK/Dutch 3.05 2.01-4.62 <0.0001 [26]
CCR2 Haplotype 2* White Dutch 4.4 1.9-9.7 <0.0001 [41]
Haplotype 2* Spanish 2.03 1.11-3.73 0.041 [27]
Haplotype 2* Swedish 3.02 1.65-5.52 0.0027 [27]
CCR5 rs2040388A German/Female 1.93 1.35-2.77 0.0003 [53]
rs2856757C German/Female 1.65 1.17-2.33 0.004 [53]
TNF# TNF-α 308AA rs1800629 US White 8.182 2.45-27.34 0.027 [73]
TNF-α 308A rs1800629 Polish 2.3 1.23-4.32 <0.01 [77]
TNF-α 308A UK/Dutch 3.1† 1.33-7.20† 0.006 [78]
TNF-α 308A German NR NR 0.0078 [79]
LTA-252G rs909253 Polish 2.98 1.67-5.29 <0.001 [77]
LTA-252GG rs909253 US White females 11.33 3.18-40.37 0.027 [73]
ANXA11 rs1049550TT Czech 0.31 0.11-0.84 0.02 [95]
Increased risk of
non-Lofgren’s
HLA DQB1*0602-DRB1*15 White Dutch 2.27 1.46-3.54† 0.0032 [32]
DRB1*12 White UK/Dutch 2.5 1.26-4.96 0.003 [26]
DRB1*12 UK 3.7 1.73-7.94 0.001 [29]
DRB1*12 Japanese 2.5 1.17-5.21 0.03 [29]
DRB1*1201 US White/AA 2.13 1.14-4.12 0.015 [34]
DRB1*10 White UK/Dutch 2.4 1.00-5.88 0.01 [26]
DRB1*14 White UK/Dutch 3.1 1.7-5.57 0.0003 [26]
DRB1*14 White Swedish 1.79 NR 0.017 [28]
DRB1*1401 US White/AA 2.29 1.21-4.34 0.011 [34]
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Gene Polymorphism Population OR CI p Ref
DRB1*14 UK 2.54 1.47-4.41 0.001 [29]
DQB1*0503/4 Dutch 2.4 1.11-5.18 0.04 [29]
DRB1*15 Finnish 1.67 1.12-2.5 0.011 [33]
DRB1*1501 US White/AA 1.7 1.18-2.46 0.003 [34]
DRB1*1101 US White/AA 1.98 1.37-2.9 <0.001 [34]
DRB3*0101 US White/AA 1.6 1.16-2.2 0.004 [34]
DRB1*1201 US AA 2.67 1.2-6.52 0.014 [34]
DPB1*0101 US AA 1.72 1.14-2.62 0.008 [34]
DRB1*0402 US white 2.57 1.02-7.28 0.043 [34]
DRB1*1501 US White 2.08 1.39-3.15 <0.001 [34]
DRB1*13 Czech 2.4 1.43-4.03 <0.02 [74]
BTNL-2 rs2076530A German 2.31 1.27-4.23 <0.006 [37]
rs2076530A White UK/Dutch 1.49 1.20-1.86 0.002 [26]
rs2076530A White Dutch 1.85 1.19-2.88 0.007 [38]
rs2076530A White US 2.03 1.32-3.12 NR [39]
rs2294878C White UK/Dutch 1.54 1.24-1.92 0.001 [26]
TNF LTA-252G rs909253 Czech 2.63 1.63-4.25 <0.00001 [74]
TNF-α 308A rs1800629 Polish 2.167 1.17-4.01 <0.05 [77]
TNF-α -857T UK/Dutch NR NR 0.002 [78]
TLR
TLR-10 rs1109695C Dutch NR NR 0.002 [68]
rs7658893A Dutch NR NR 0.001 [68]
TLR-1 rs5743604G Dutch NR NR 0.003 [68]
rs5743594G Dutch NR NR 0.049 [68]
SLC11A1
Allele 2£ US AA 0.48 0.28-0.81 0.014 [69]
Allele 3¥ Polish 1.68 1.01-2.81 0.04 [71]
Allele 3¥ Turkish 2.69 1.61-4.47 <0.001 [70]
Allele 3¥ Greek 1.52 1.08-4.52 0.015 [72]
INT4 Turkish 2.75 1.68-4.52 <0.001 [70]
ANXA11 rs1049550C German 1.54 1.23-1.92 0.00014 [94]
rs1049550T Czech 0.77 NR 0.04 [95]
rs2573346C German 1.55 1.24-1.92 0.00008 [94]
Decreased risk
HLA DRB1*01 White Swedish 0.61 NR 0.003 [28]
DRB1*01 White UK/Dutch 0.5 0.35-0.82 0.001 [26]
DRB1*01 UK 0.5 0.34-0.76 0.001 [29]
DRB1*01 Dutch 0.4 0.23-0.76 0.006 [29]
DRB1*01 Japanese 0.12 0.03-0.52 0.001 [29]
DRB1*01 Finnish 0.43 0.26-0.72 0.001 [109]
DRB1*04 White UK/Dutch 0.6 0.46-0.92 0.02 [26]
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Gene Polymorphism Population OR CI p Ref
DRB1*0401 US White/AA 0.48 0.28-0.8 0.003 [34]
DRB1*04 UK 0.54 0.35-0.84 0.008 [29]
DQB1*0301 UK 0.69 0.51-0.94 0.02 [29]
DQB1*0603 US Males 0.5 NR NR [34]
DRB1*1503 US AA 0.56 0.3-0.99 0.44 [34]
DRB1*0401 Us white 0.44 0.25-0.77 0.003 [34]
DRB1*07 Czech 0.40† 0.21-0.76† 0.0031 [74]
CCR2
CCR2-64I Japanese 0.37 0.21-0.67 0.0007 [43]
US: United States of America
UK: United Kingdom
AA: African American.
HLA: Human Leukocyte Antigen.
TLR: Toll-like receptor
NR: Not reported.
£Allele 2: T(GT)5AC(GT)5AC(GT)10
¥Allele 3: T(GT)5AC(GT)5AC(GT)9
*haplotype 2: (A at -6752,A at 3000, T at 3547 and T at 4385)
#TNF association with erythema nodosum
† Values calculated by authors from raw data provided in original manuscript.
Table 1. Association of genetic markers with risk of developing sarcoidosis.
Numerous studies  have been published investigating the association of  genetic  markers
with the risk of developing sarcoidosis or the risk of disease severity,  disease course or
specific  organ  involvement  [5-11].  Genetic  polymorphisms,  that  are  functional,  can
influence  the  immune  system’s  response  or  function  leading  to  active,  progressive  dis‐
ease or self-resolving, limited disease. Although it is yet unknown if,  and how, many of
the genetic polymorphisms detected can influence the immune response, they do provide
new insight on pathways that are potentially involved in the pathogenesis of sarcoidosis
and provide new potential therapeutic targets.
2. Receptors
2.1. HLA region
The HLA system plays an important role in the immune response and has been associated
with various autoimmune diseases [24]. The HLA genes are encoded on chromosome 6 and
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consist of over 200 genes [25]. HLA class I molecules, HLA-A, B and C, are expressed by most
somatic cells and are important in the immune response [25]. They are composed of an α
polypeptide chain, which is coded by the class I genes, and a β chain which is coded by the
β2-microglobulin gene on chromosome 15 [25]. The HLA class II genes code for the α and β
polypeptides of the class II molecule [25]. The HLA class II molecules are designated by 3
letters, the first (D) represents the class, the second (M,O,P,Q or R) represent the family and
the third (A or B) represent the α or β chains [25]. The numbers that precedes the asterisk
indicates the gene and the numbers following the asterisk represent the allelic variant of that
gene [25]. HLA class II molecules are primarily expressed on immune cells. The HLA class II
molecules play an important role in the immune response presenting antigens to the effector
cells and induce activation of the immune cells [25].
Sarcoidosis can present insidiously (non-Lofgren’s syndrome) or present acutely with systemic
symptoms, acute arthritis, erythema nodosum and bilateral hilar lymphadenopathy, more
commonly known as Lofgren’s syndrome (LS) [1]. Several HLA alleles have been associated
with LS. HLA-DRB1 is the most common and has been reported in a white Dutch and UK
cohorts [26], Spanish and Swedish cohorts (HLA-DRB1*0301) [27], a Scandinavian cohort
(HLA-DRB1*03) [28] and a Dutch cohort (HLA-DRB1*03-DQB1*0201) [29]. In addition, HLA-
DQB1*0201 has been reported In White UK and Dutch cohorts [30]. HLA-DRB1*03 and HLA-
DQB1*02 are in strong LD [30]. In addition, 2 SNPs (rs3087456 and rs11074932) in the major
histocompatibility complex class II transactivator (MHC2TA) gene, which acts as a master
regulator for the expression of MHC class II molecules, were found to be associated with LS
independent of HLA-DRB1*03 [31].
Several HLA alleles have also been associated with increased risk of developing non-LS
sarcoidosis. HLA-DQB1*0602 has been associated with increased risk of non-LS sarcoidosis in
a Dutch cohort [32]. HLA-DRB1*14, *12 and *10 have been associated with increased risk of
sarcoidosis in a white Dutch and British cohort [26], and HLA-DRB1*12 and DRB1*14 in cohorts
from the UK, Netherlands and Japan [29] whereas HLA-DRB1*1501 was associated with risk
of sarcoidosis in a Finnish cohort [33]. HLA-DRB1*1201, *1401, *1501, *1101 and HLA-
DRB3*0101 were associated with sarcoidosis in the ACCESS cohort in the USA [34].
In contrast, HLA alleles that have been associated with decreased risk (protective) for sarcoi‐
dosis included HLA-DRB1*01 and *04 in white Dutch and UK cohorts [26] and HLA-DRB1*01
in cohorts from the UK, Netherlands and Japan [29] and HLA-DRB1*0101 was protective in a
Finnish cohort [33]. In the ACCESS cohort, HLA-DRB1*0401 was protective for the overall
cohort (African Americans and Caucasians) [34].
Some HLA markers are gender or ethnic specific in their association with sarcoidosis. In the
ACCESS cohort, HLA-DRB1*1101 was associated with increased risk more in males than
females whereas HLA-DRB1*0401 was associated with decreased risk more in males than
females, [34] HLA-DQB1*0603 was a risk factor for females but a protective factor for males.
[34] For blacks in the ACCESS cohort, HLA-DRB1*1201 and HLA-DPB1*1503 were associated
with increased risk of sarcoidosis and HLA-DRB1*1503 was associated with decreased risk of
sarcoidosis [34] whereas in whites, HLA-DRB1*0402 and DRB1*1501 were associated with
increased risk whereas HLA-DRB1*0401 was protective against sarcoidosis [34].
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Overall, HLA-DRB1 molecules appear to play an important role in the pathogenesis of
sarcoidosis either by recognizing specific antigen(s) or mounting different immune responses
to different antigen(s). A better understanding of the role of HLA molecules in the pathogenesis
of sarcoidosis could move us a step closer to potentially identifying the antigen(s) that trigger
sarcoidosis [35].
2.2. BTNL2
The butyrophilin like 2 gene (BTNL2) belongs to the immunoglobulin gene superfamily and
is related to the CD80 and CD86 co-stimulatory receptors. [7] In a mouse model, it was shown
that BTNL2 binds to activated T-cells and inhibits their proliferation. [36] BTNL-2 was first
linked to sarcoidosis when a GWAS in 63 German families with sarcoidosis identified a linkage
to chromosome 6p21. [5] Further investigation found an association between SNP rs2076530A
in the BTNL2 gene and sarcoidosis. [7] rs2076530A produces an alternative splice site that
results in an early stop codon and a truncated, non-functional protein as a final product. [7]
These findings were replicated in another German sarcoidosis cohort [37]. In a white British
and Dutch cohorts, the SNPs rs2076530A and rs2294878C both showed an association with
increased risk of sarcoidosis whereas haplotype 4 (which included rs2076530G and
rs2294878A) had a protective association [26]. The SNP rs2076530A was associated with non-
Lofgren’s sarcoidosis and a gene dose effect was detected (AG vs GG OR 1.98, AA vs GG OR
2.63) [26]. There was strong linkage disequilibrium (LD) between BTNL2 haplotype 2 and
HLA-DRB1*03 and between BTNL2 haplotype 4 and HLA-DRB1*01. [26] When the association
of rs2076530A with the risk of sarcoidosis was analyzed in the context of HLA-DRB1, the
rs2076530A association no longer held whereas the association of HLA-DRB1*12 and *14 with
the risk of sarcoidosis persisted. [26] In a Dutch cohort, BTNL2 rs2076530A was associated
with increased risk of sarcoidosis and a strong LD was found with HLA-DRB1*15. [38]
rs2076530A was also associated with an increased risk of sarcoidosis in an American Caucasian
cohort whereas in an African American cohort, the BTNL2 gene risk and the HLA-DRB1 gene
risk negated each other. [39] In the same cohort, BTNL2 rs3117099T was associated with
Lofgren’s syndrome, similar but stronger association was also detected for haplotype 2 which
contains rs3117099T. [26] The association of both haplotype 2 and HLA-DRB1*03 with
Lofgren’s syndrome remained significant after adjusting for each other and was stronger when
both were present and protective against sarcoidosis when both were absent [26].
2.3. CCR2
CCR2 is a receptor for the chemokines CCL5, CCL2 and CCL3 that play an important role in
recruiting monocytes, T-cells and other inflammatory cells. [40, 41] The association of 8 SNPs
in the CCR2 gene with sarcoidosis was investigated in a white Dutch sarcoidosis population,
a haplotype that consisted of 4 unique alleles (A at -6752,A at 3000, T at 3547 and T at 4385)
was associated with LS, this association remained significant after adjustment for HLA-
DRB1*0301-DQB1*0201 and female gender (both of which have been associated with LS). [41]
No difference was seen between non-LS and controls. [41] This association and independence
from HLA-DRB1 was confirmed in Swedish and Spanish sarcoidosis cohorts. [27] Similar
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findings were found in a Czech cohort although the difference did not reach statistical
significance. [40] No association was detected between 3 SNPs in CCR2 and sarcoidosis in a
German cohort. [42] CCR2-64I mutation (A substitution mutation where isoleucine replaces
valine in the transmembrane region) was found it to be protective against sarcoidosis in a
Japanese cohort. [43]
2.4. CCR5
The CCR5 gene is located on the short arm of chromosome 3 [44] and codes for a receptor for
several chemokines including CCL3, CCL4, CCL5 and CCL8. [45] These chemokines play an
important role in lymphocyte and monocyte recruitment and activation in sarcoidosis. [46,
47] In Sarcoidosis, CCR5 expression is up-regulated in Bronchoalveolar lavage (BAL) macro‐
phages and lymphocytes [48, 49] and levels of the CCR5 ligands, CCL3 and CCL5, correlate
with risk of disease progression. [50-52] The CCR5Δ32 null allele results a 32bp deletion in the
CCR5 gene and produces a non-functional receptor that is unable to bind to its ligand [53]. The
A allele at position -5663 (rs2040388) and the C allele at position -3900 (rs2856757), both of
which are part of the HHC haplotype, were associated with LS in a German cohort, particularly
in females [53]. No association between 8 SNPs in the CCR5 gene and risk of sarcoidosis was
detected in a white Dutch and UK cohorts but an association was noted with severity of lung
disease. [54]
2.5. CARD15
CARD15/NOD2 is an intracellular molecule that is part of the innate immunity which recog‐
nizes muramyl dipeptide, a component of gram-positive and gram-negative bacteria cell wall
[55]. It was first identified in association with the risk of Crohn’s disease. [55] No significant
association was detected between CARD15 polymorphisms and risk of sarcoidosis in German
[56, 57], Japanese [58], Danish [59, 60] cohorts. In contrast, an association was noted with risk
of disease in a Greek cohort [61].
2.6. Toll-Like receptors
Toll-like receptors (TLR) are transmembrane proteins that are critical in the innate immune
system. [62] They are also known as pattern recognition receptors as they recognize specific
microbial structures. [62] So far, 11 TLRs have been recognized. [62] Several studies in German
and Dutch cohorts have investigated the potential association of polymorphisms in the TLR4,
TLR2 and TLR9 genes with sarcoidosis but found no association with the risk of sarcoidosis.
[63-67] One study in a German cohort suggested an association with chronic sarcoidosis. [63]
In a Dutch cohort, SNPs rs1109695 and rs7658893 in the TLR-10 gene and rs57436004 and
rs5743594 in the TLR-1 gene were associated with the risk of sarcoidosis. [68] None of the 4
SNPs were significantly different between remitting and chronic disease but they did differ
significantly between healthy controls and sarcoidosis patients with chronic/progressive
disease. [68]
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2.7. SLC11A1 (NRAMP1, Natural Resistance-Associated Macrophage Protein Gene)
The SLC11A1 gene encodes a macrophage-specific, membrane protein whose function
involves transport and appears to be important in the early stages of macrophage activation.
[69] In US African Americans, a repeat polymorphism in 5’ region (allele 2) of the gene was
protective against sarcoidosis. [69] This finding was replicated in Polish, Turkish and Greek
cohorts where the opposite polymorphism (allele 3) was associated with increased risk of
sarcoidosis. [70-72] In the Turkish cohort, polymorphism in INT4 was also associated with
increased risk of sarcoidosis but this association was not noted in the other cohorts. [70]
3. Cytokines/Chemokines
3.1. TNF-α and lymphotoxin-A (LTA, TNF-β)
TNF-α and LTA genes are located within the MHC class III region on chromosome 6p21.3
[73-75]. TNF-α plays a pivotal role in sarcoidosis [76]. It is produced by alveolar macrophages
and high levels of spontaneous and stimulated release of TNF-α by macrophages from
sarcoidosis patients correlates with disease severity. [76] Several Loci in the TNF-α gene have
been studied including -307 (previously mislabeled as -308), -857, -863.
LTA-252G (rs909253)  allele  was associated with sarcoidosis  in Czech and Polish cohorts
[77] and TNF-α-308A (rs1800629) allele was associated with sarcoidosis in Polish and Czech
sarcoidosis cohorts [77]. There was a strong LD between the TNF-α 308A, LTA252G alleles
and HLA-DRB1*03 which has been associated with LS [74]. An association between TNF-
α 308A (rs1800629) allele and LS and between TNF-α -857T allele and non-LS sarcoidosis
was  also  found  in  a  British  and  Dutch  cohort  [78]  and  German  cohorts  [79-81].  An
association was found between the TNF-α -308 (rs1800629) and LTA252G(rs909253) SNPs
and erythema nodosum in  US white  women [73]  but  no  association  between polymor‐
phisms in the TNF-α gene and sarcoidosis in African Americans was detected. [82] There
was also an increased frequency of the -857T allele in British and Dutch sarcoidosis patients
compared to controls. [78]
The relationship between serum TNF-α levels and genotypes is unclear, one study found an
increased serum TNF-α levels with the TNF-α-307(8)G and the TNF-α -238A alleles in a
sarcoidosis population but not normal controls, [83] whereas another study did not detect any
association in the spontaneous or stimulated release of TNF-α from BAL and PBMC cells with
the TNF-α 308 and TNF-β (intron 1) genotypes. [84]
The  TNF-α-863  position  lies  further  upstream in  the  promoter  region.  It  influences  the
binding of NF-kB p50-p50 to the promoter region and inhibiting TNF-α production. The
A  allele  variant  inhibits  the  binding  of  NF-kB  p50-p50  and  thus  leading  to  a  higher
production of TNF-α. [85] There was a marginal association of the allele TNF-1031A with
the  risk  of  sarcoidosis  and an  association  of  TNF-1031A and TNF-α-863A with  chronic
disease in an Indian cohort. [83]
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3.2. TGF-β
TGF-β is a growth factor with 3 isoforms: TGF-β1, TGF-β2 and TGF-β3. They have nearly
identical biological properties but the functional properties are usually attributed to TGF-β1.
[86] TGF-β induces the synthesis of extracellular matrix and decreases matrix degradation, has
immunomodulatory properties acting as a mediator regulating chemotaxis and fibroblasts and
has been implicated in pulmonary fibrosis. [86, 87] The variant allele C of -509T/C and C of
codon 10 are associated with higher TGF-β1 protein levels in the serum and the codon 10
variant is associated with increased mRNA levels in PBMC. [88, 89] TGF-β1 levels in the BAL
and alveolar macrophage supernatant are higher in patients with active sarcoidosis and
especially in those with pulmonary function changes, [90] there was also a positive correlation
with BAL lymphocytosis. [90]
No association was found between sarcoidosis and 2 polymorphisms (codon 10, T869C) in the
TGF-β1 gene in a Japanese sarcoidosis cohort and no relationship with Scadding chest x-ray
stage was found either. [91] Codon 10 was also not associated with sarcoidosis in a German
cohort [92]. No association between polymorphisms in the TGF-β1, TGF-β2 and TGF-β3 genes
and sarcoidosis was detected in a white Dutch cohort. [93]
4. Signaling molecules
4.1. Annexin A11
The ANXA11 gene plays a role in the apoptosis pathway and depletion or dysfunction of the
Annexin A11 protein may impair cell apoptosis and the down-regulation of the immune
response [8]. A GWAS analysis in a German sarcoidosis cohort found a strong association
between several SNPs in the annexin A11 (ANXA11) gene on chromosome 10 (10q22.3) and
the risk of sarcoidosis. [8] This association was confirmed in a separate German cohort were
the C allele of both rs1049550 and rs2573346 were associated with the development of sarcoi‐
dosis. [94] The association of rs1049550 with risk of sarcoidosis was also confirmed in a Czech
cohort [95].
5. Others
5.1. Angiotensin Converting Enzyme (ACE)
Serum ACE is one of the biochemical markers that reflect disease activity in sarcoidosis. [1]
Serum ACE levels do correlate with ACE genotype, with genotype D/D having the highest
levels and I/I the lowest. [96-100] Several studies have investigated the association of ACE
genotypes with sarcoidosis. In an African American cohort, the DD genotype was associated
with increased risk of sarcoidosis, but not extent or severity, and the association was stronger
when a family history of sarcoidosis was taken into account. [101] This association was not
noted in a later study in African Americans. [82] In a Japanese cohort, the DD genotype was
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associated with increased risk of sarcoidosis in their female patients. [96] No association was
detected in a US Caucasian cohort [101]. Otherwise, no association between polymorphisms
in the ACE gene and risk of sarcoidosis was detected in German, Dutch, Italian, British, Finnish
and Czech sarcoidosis cohorts. [97-100, 102, 103]
The angiotensin II receptor 1 genotype AA and CC potentially increase the risk of sarcoidosis
in males in a German cohort but these findings were not replicated in a Dutch cohort. [97, 98]
No association existed between the angiotension II receptor 1 and 2 genotypes and sarcoidosis
in a Japanese cohort. [104]
5.2. IL-10 and CD40
No association between polymorphisms in the IL-10 or the CD40 gene and risk of sarcoidosis
in Japanese cohorts was detected. [105, 106]
Genetic markers and disease course / organ involvement (Table 2):
Gene Polymorphism Population OR CI p Ref
Progressive Pulmonary
disease
HLA DQB1*0602 AA NR NR 0.032 [107]
DRB1*07 Scandinavian 0.44 NR 0.009 [28]
DRB1*14 Scandinavian 2.14 NR 0.005 [28]
DRB1*15 Scandinavian 1.55 NR 0.011 [28]
DRB1*01 Scandinavian 0.41 NR <0.001 [28]
DRB1*03 Scandinavian 5.42 NR <0.001 [28]
DRB1*03 Finnish 2.22 1.20-4.1 0.011 [33]
BTNL 2 rs2076530 Dutch 1.84 1.06-3.21 0.03 [38]
CCR5 HHC haplotype British 6.8* 2.5-18.0 0.0045 [54]
HHC haplotype Dutch 9* 3.5-23.1 0.0009 [54]
CARD15/NOD2 rs2066844T British 4.1 1.0-15.5 0.04 [110]
IL23 Rs11209026A German 0.63 0.5-0.79 <0.001 [117]
TNF
TNF-α 308A Dutch 0.43 0.31-0.61 <0.001 [75]
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Gene Polymorphism Population OR CI p Ref
TNF-α 308T Italian 3.53 1.66-7.5 <0.001 [77]
TGF- β
TGF-β1 rs1800469 US white 2.5 1.3-4.5 0.005 [118]
TGF- β3 rs3917165A US White 7.9 2.1-30.9 P=0.01 [118]
TGF- β3 rs3917200C US White 5.1 1.6-17.7 P=0.05 [118]
GREM1 rs1919364CC Dutch 6.37 2.89-14.1 <0.001 [120]
ANXA11 rs1049550T Czech 0.61 0.41-0.89 0.01 [95]
Ophthalmic
HLA DRB1*0401 AA/White 3.49 1.62-7.54 <0.0008 [34]
DRB1*0401-DQB10301 UK 3.4 1.64-7.08 0.001 [29]
DRB1*03-DQB1*0201 UK 0.21 0.08-0.54 <0.0001 [29]
Hypercalcemia PBB1-0101 US white 4.28 1.45-12.6 0.005 [34]
* OR at 4 years
HLA : Human Leukocyte Antigen
Table 2. Association of genetic markers with sarcoidosis disease course, severity and/or organ invovlement.
6. Receptors
6.1. HLA region
HLA genetic markers were also investigated for their association with sarcoidosis disease
course, severity and/or organ involvement. HLA-DQB1*0602 was associated with radiograph‐
ic progression in an African American cohort [107], advanced pulmonary disease and uveitis
in Dutch cohorts [30, 108] whereas in a Scandinavian cohort, HLA-DRB1*07,*14 and *15 were
associated with progressive pulmonary disease whereas *01 and *03 were associated with non-
progressive disease [28]. In a Finnish cohort, HLA-DRB1*03 was associated with resolving
disease [109].
6.2. BTNL-2
In a Dutch cohort, BTNL2 16071A variant was associated with increased risk of progressive or
persistent pulmonary sarcoidosis [38].
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6.3. CCR5
CCR5Δ32 null  allele  was associated with the need for  immunosuppressive therapy in a
Czech cohort  [40].  The haplotype HHC (-5663A, -3900C, -3458T, -2459G, -2135T, -2086G,
-1835C, Δ32 wt) was strongly associated with the presence of parenchymal disease in British
and Dutch cohorts at presentation, 2 and 4 years of follow up [54]. The haplotype HHC
was also associated with lower forced expiratory volume in the first second (FEV1), forced
vital  capacity  (FVC),  bronchoalveolar  lavage  neutrophilia  (>4%)  but  not  other  organ
involvement with Sarcoidosis [54].
6.4. CARD15/NOD2
In a British cohort, there was an association between allele T at loci 2104 (rs2066844) and the
risk of radiographic Scadding stage IV at year 4 of follow up and an association between the
allele G at loci 1761 with better lung function, defined by DLCO, at presentation, 2 and 4 years
of follow up. [110] Interestingly, in a study in Crohn’s disease patients, variants in loci 2104,
2722 and 3020 were associated with decreased number of T-regulatory cells in the lamina
propria. [111] T-regulatory cells have been implicated to have a role in the immune pathogen‐
esis of sarcoidosis but their exact role is yet unknown. [3, 112, 113]
7. Cytokines/Chemokines
7.1. TNF-α 308, LTA252 (TNF-β)
A higher representation of the TNF-α308A allele was found in a Dutch cohort with non-
persistent disease compared to persistent disease. [75] In a Polish cohort, TNF-α308 A/A was
associated with disease remission. [77]
7.2. TGFβ
In a white Dutch cohort, there was an increased frequency of the A allele in rs3917165 in the
TGF-β3 gene in the fibrotic group compared to the acute/chronic groups [93], in addition, the
C allele in rs3917200 was more frequent in the fibrotic group compared to the acute/chronic
groups. [93] In another study, white American sarcoidosis patients who had CC homozygosity
at position -509 (rs1800469) were more likely to have parenchymal disease [118].
7.3. IL-23
IL-23 is a pro-inflammatory cytokine that stimulate Th-17 cells to produce IL-17 and other
cytokines and has a role in a number of autoimmune diseases [114, 115]. Polymorphisms in
rs11209026 can affect serum IL-17A levels in rheumatoid arthritis patients [116]. In a German
cohort, rs11209026A was protective against chronic sarcoidosis [117].
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8. Signaling
8.1. GREM1
Gremlin, encoded by GREM1, is a secreted glycoprotein and antagonizes bone morphogenetic
protein (BMP) by forming heterodimers with BMP-2, BMP-4 and BMP-7 preventing BMP from
interacting with its ligand and subsequent downstream signaling. [119] Dutch sarcoidosis
patients with the CC genotype for rs1919364 in GREM1 had a 6 fold increased risk of devel‐
oping fibrotic lung disease. [120]
8.2. Annexin A11
In a Czech cohort, rs1049550 T-allele was protective against parenchymal disease (Scadding
stages II-IV) [95].
9. Other
9.1. COX2
In a Spanish cohort, there was an association between the CC genotype of the COX2.8473
polymorphism and increased risk of sarcoidosis [121] and an association of the C-allele of the
COX2.3050 with systemic sarcoidosis versus non-systemic sarcoidosis [122].
9.2. IL-10 and CD40
There were no associations between polymorphisms in the IL-10 and CD40 gene in Japanese
cohorts and the risk of sarcoidosis. [105, 106]
10. Organ involvement
A few genetic markers have also been associated with organ involvement in sarcoidosis. In the
ACCESS study, HLA-DRB3 was associated with bone marrow involvement in blacks, HLA-
DPB1*0101 with hypercalcemia in whites, HLA-DRB1*0401 with parotid and salivary gland
involvement in blacks and HLA-DRB1*0401 was found to have possible association with eye
involvement [34]. In a cohort from the UK, HLA-DRB1*0401-DQB1*0301 was associated with
increased risk of uveitis whereas HLA-DRB1*03 and DQB1*0201 were protective for uveitis.
[29] In a Japanese cohort, HLA-DRB1*15 and DQB1*0602 were associated with skin disease
and HLA-DRB1*0803 with neurosarcoidosis. [29] In a Japanese cohort, polymorphisms in the
CTLA-4 gene were associated with BAL lymphocytosis, ocular involvement and multi-organ
involvement. [123, 124]
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11. Conclusions
Sarcoidosis is a complex disease with variable presentations, course and organ involvement,
as such, it is no surprise that research into the genetic basis of the disease yields complex and
variable results. This is supported by the variability in presentation, course and organ
involvement between various ethnic groups. To add to this complexity, linkage disequilibrium
(LD) occurs when alleles at two loci are not independent of each other. As such, when one
genetic marker is identified as associated with a disease or trait, then any allele in strong LD
with that marker could be the actual link to the disease. For example, BTNL-2 has been
associated with increased risk of sarcoidosis [5, 7, 8, 26, 37] but has also been shown to be in
strong LD with HLA markers [26].
HLA molecules play an important role in antigen presentation and immune stimulation [24,
25]. The association of HLA markers with increased risk of sarcoidosis or specific organ
involvement could potentially lead to identification of a causative agent(s), as seen in chronic
beryllium disease [125], and a recent study has shown an interaction between genetics and
immune response to certain environmental antigens [22]. Chronic beryllium disease, a
granulomatous disorder that is caused by exposure to beryllium and resembles sarcoidosis,
has been associated with HLA-DP-βGLu69 as a genetic risk factor [126]. Studies have shown
that HLA-DP-βGlu69 interacts with beryllium with subsequent stimulation of the immune
response [125]. In addition, the identification of genetic markers that are associated with
sarcoidosis might uncover novel pathways not previously identified or suspected as contrib‐
utors to disease pathogenesis, which could subsequently lead to identification of new thera‐
peutic targets.
Further research is still needed to clarify the associations of the various genetic markers with
risk and prognosis of disease and large validation studies will be needed to confirm these
associations. Proper phenotyping of cases and stratification according to ethnicity and gender
when analyzing genetic studies is extremely important. Several studies have shown opposite
associations between gender and/or ethnicity and genetic markers when the analysis was
stratified by gender and/or ethnicity [53]. In addition, the interaction between two or more
distinct SNPs or haplotypes in sarcoidosis has yet to be studied [127].
So what role does genetic testing have in the clinical care of sarcoidosis patients? At this stage,
genetic testing has no identifiable role in the clinical arena. The odds of a first or second degree
relative of a sarcoidosis patient also having sarcoidosis are 4.6 and the familial relative risk
was larger in sibs than in parents and higher in Whites than African Americans [4]. This said,
the absolute risk and attributable risk for a sib or parent of a sarcoidosis patients is approxi‐
mately 1% and as such, screening family members, clinically or genetically, is not recom‐
mended [4].
Potential future applications of genetic testing in the clinical arena include prognostication on
disease course which will aid in determining intensity of follow up, prognostication on
potential organ involvement which will influence frequency and intensity of screening for
sarcoidosis involvement, and potentially a role for pharmacogenetics in guiding immunomo‐
dulatory therapy.
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